glp-1 and lamotrigine receptor agonists in people with epilepsy: A scoping review of clinical data, safety, therapeutic implications FDA: Arrhythmia Risk With Lamotrigine

A major phase 2 trial in the New England Journal of Medicine 1 found: After 24 weeks: Weight loss ranged from 7.2% with the lowest dose of retatrutide to 17.5% with the highest dose (compared to just 1.6% with placebo) After 48 weeks: Participants on the 12 mg dose lost an average of 24.2% of their starting weight (placebo group: only 2.1%) Most participants (64-100%) taking retatrutide achieved meaningful weight loss of 5% or more, while only 27% of placebo takers reached this goal Managing Retatrutide Side Effects The main side effects of retatrutide affect your digestive system: Nausea Vomiting Diarrhea Bloating These effects are usually not severe and tend to lessen as your body adjusts to the medication

5 With prandial insulin (AWARD-2) Patients were randomised to dulaglutide once weekly or insulin glargine once daily, both in combination with prandial insulin lispro three times daily, with or without metformin

Freudenthal, Moncrieff)

Use in children under 12 years is not recommended

Semaglutide: The Breakthrough GLP-1 Semaglutide was the first GLP-1 drug to show double-digit percentage weight loss in large clinical trials